Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study
Authors:
Open Access
- 9 November 2018
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 83 (1) , 201-207
Abstract
Sunitinib is approved for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNETs) in patients with unresectable, locally advanced or metastatic disease. Safety and efficacy data in Japanese patients are limited. We report outcomes from a post-marketing surveillance study of sunitinib treatment in Japanese patients.Keywords
Funding Information
- Pfizer Japan
This publication has 22 references indexed in Scilit:
- Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumorInvestigational New Drugs, 2013
- Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinibTherapeutic Advances in Gastroenterology, 2013
- Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 TrialJapanese Journal of Clinical Oncology, 2012
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell CarcinomaJapanese Journal of Clinical Oncology, 2010
- A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and SafetyJapanese Journal of Clinical Oncology, 2009
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreasActa Oncologica, 2007
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell, 2005
- VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesisCancer Cell, 2002